

Ready for Osteoarthritis Pain Relief?

SYNVISC® and Synvisc-One® can help^{1,2}

People living with osteoarthritis (OA) of the knee have a number of treatment choices for pain management, two of which are **SYNVISC®** and **Synvisc-One®** (hylan G-F 20).^{1,2} The following information provides answers to questions you may have about treatment coverage options for these products.

What is osteoarthritis of the knee?

The causes of osteoarthritis of the knee are not clear.³ It is a chronic, degenerative joint disease⁴ where cartilage that cushions the ends of bones in the knee joint gradually deteriorates.⁵ Genetic predisposition, knee injury or trauma, excess body weight, and older age are some of the risk factors contributing to this disease.⁵

What are SYNVISC®/Synvisc-One®?

SYNVISC®/Synvisc-One® are viscosupplement injections that mimic synovial fluid^{1,2}, the shock-absorbing lubricant located within the knee joint.⁶ Their properties and characteristics are similar to healthy synovial fluid and are used to treat osteoarthritis – of the knee, hip, shoulder or ankle.^{1,2}

SYNVISC® is used to treat pain associated with osteoarthritis of the knee, hip, ankle and shoulder.¹

Synvisc-One® is used to treat pain associated with osteoarthritis of the knee.²

How are SYNVISC® products used?

For osteoarthritis of the knee, **SYNVISC®** is injected weekly for 3 weeks, whereas **Synvisc-One®** is given as a single injection. The maximum recommended dosage of **SYNVISC®** for osteoarthritis of the knee is six injections within six months, with a minimum of four weeks between treatment regimens. For **Synvisc-One®**, the injection may be repeated 6 months after the first injection, if justified by the patient's symptoms.^{1,2}

Please refer to the **SYNVISC®** Instructions for Use for dosage guidelines for osteoarthritis of the hip, ankle and shoulder.

How are SYNVISC® products made available?

If you are interested in **SYNVISC®/Synvisc-One®**, talk to your doctor.

1. Your doctor may dispense **SYNVISC®/Synvisc-One®** in his or her office and administer the injection right away.
- OR
2. You may pick up **SYNVISC®/Synvisc-One®** from your pharmacy with a prescription from your doctor, and return to your doctor's office for the injection. **Your pharmacy may need to order the product if they do not have it in stock, which may take a few days.**

Are SYNVISC® products covered by health benefit plans?

Each insurance plan is different. Information can be found in your plan's Benefits Booklet, usually in the Drug Benefits section or Extended Health Benefits section under Medical Services and Supplies.

Some insurers allow **SYNVISC®** products to be processed directly at the pharmacy. With your drug card, the pharmacy can process the claim electronically using the appropriate identification number for your benefits plan. Other insurers may require you to pay for the product first and then submit the receipt with a claim form to your insurance company.

It is important to follow the instructions carefully as each plan is different. It is recommended that you contact your insurance plan directly to verify your coverage and instructions on how to submit your claim.

For your convenience, the **Benefit Plan Coverage Summary** on the next page provides specific **SYNVISC®** Product Identification Numbers for major Canadian insurers. These may be helpful when contacting your insurance provider.

Coverage Information for SYNVISC® and Synvisc-One®

Insurer or PBM (PBM card)	Coverage Likely Found Under	Identification	
		SYNVISC®	Synvisc-One®
Manulife Financial (ESC)	Drug Benefits Plan or Extended Health Benefits Plan	00962325 00965294	00965014
Sun Life Financial	Drug Benefits Plan	00962325 00965294	00965014
Alberta Blue Cross	Drug Benefits Plan or Supplementary Benefits Plan	00962325 00965294	00965014
Canada Life	Extended Health Service Benefit	Viscosupplementation	Viscosupplementation
Claim Secure	Extended Health Care Benefit	Contact Claim Secure Directly	Contact Claim Secure Directly
Greenshield	Drug Benefit for Insured Plans	00962325 00965294	00965014
Desjardins	Drug Benefits Plan or Supplementary Benefits Plan	00962325 00965294	00965014
Beneva	Drug Benefits Plan or Supplementary Benefits Plan	00962325 00965294	00965014

For more information:

Please call 1-800-796-7991 and a specialist will be pleased to help you.

You can also visit the **SYNVISC®/Synvisc-One®** website at www.synviscone.ca.

Important Treatment Considerations

SYNVISC® (hylan G-F 20) is an intra-articular injection used to treat pain associated with osteoarthritis of the knee, hip, ankle and shoulder. SYNVISIC® contains small amounts of avian protein and should not be used in patients with related hypersensitivities. Adverse events involving the injected joint after intra-articular injections of SYNVISIC® may include transient pain and/or swelling and/or effusion. Cases of acute inflammation, characterized by joint pain, swelling, effusion and sometimes joint warmth and/or stiffness, have been reported following an intra-articular injection of SYNVISIC®. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported. The post-marketing experience has identified the following systemic events to occur rarely with SYNVISIC® administration: rash, hives, itching, fever, nausea, headache, dizziness, chills, muscle cramps, paresthesia, peripheral edema, malaise, respiratory difficulties, flushing, and facial swelling. If venous or lymphatic stasis is present in the affected limb, SYNVISIC® should not be injected into the joint. SYNVISIC® should not be used in infected or severely inflamed joints or in patients having skin diseases or infections in the area of the injection site. SYNVISIC® should not be injected intravascularly, extra-articularly, or into the synovial tissues and capsule. Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence. Some cases of skin necrosis have been reported after intra-articular use of hyaluronic acid. Patients should be instructed to contact their treating physician if signs of skin disorder (such as change of colour or open sores) appear.¹

Synvisc-One® (hylan G-F 20) is an intra-articular injection used to treat pain associated with osteoarthritis of the knee. Synvisc-One® contains small amounts of avian protein and should not be used in patients with related hypersensitivities. Adverse events involving the injected knee after intra-articular injections of Synvisc-One® may include transient pain and/or swelling and/or effusion. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported. The post-marketing experience has identified the following systemic events to occur rarely with Synvisc-One® administration: rash, hives, itching, fever, nausea, headache, dizziness, chills, muscle cramps, paresthesia, peripheral edema, malaise, respiratory difficulties, flushing, and facial swelling. If venous or lymphatic stasis is present, Synvisc-One® should not be injected into the knee. Synvisc-One® should not be used in infected or severely inflamed knees or in patients having skin diseases or infections in the area of the injection site. Synvisc-One® should not be injected intravascularly, extra-articularly, or into the synovial tissues and capsule. Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence. Some cases of skin necrosis have been reported after intra-articular use of hyaluronic acid. Patients should be instructed to contact their treating physician if signs of skin disorder (such as change of colour or open sores) appear.²

References:

1. SYNVISIC® Instructions for Use, Genzyme Canada Inc., June 10, 2023
2. Synvisc-One® Instructions for Use, Genzyme Canada Inc., June 9, 2023.
3. Arthritis Foundation. Osteoarthritis of the knee. Accessed April 28, 2023 at: <https://www.arthritis.org/diseases/more-about/osteoarthritis-of-the-knee>.
4. Johns Hopkins Medicine. Osteoarthritis. Accessed July 11, 2023 at: <https://www.hopkinsmedicine.org/health/conditions-and-diseases/arthritis/osteoarthritis>.
5. Mayo Clinic. Osteoarthritis: symptoms and causes. Accessed April 28, 2023 at: <https://www.mayoclinic.org/diseases-conditions/osteoarthritis/symptoms-causes/syc-20351925>.
6. Tamer TM. Hyaluronan and synovial joint: function, distribution and healing. Interdiscip Toxicol. 2013;6(3):111-125.